Podcasts about Translational medicine

We've all heard stories about someone who went in for surgery and came out...different. A grandmother who struggled with names after hip replacement, or an uncle who seemed foggy for months following cardiac bypass. But why does this happen to some people while others bounce right back?This week, we explore this question with Dr. Martin Angst, a professor of anesthesiology at Stanford who's studying the biological factors that determine cognitive outcomes after surgery. With support from the Knight Initiative for Brain Resilience, Martin and his team are following hundreds of cardiac surgery patients, tracking everything from blood biomarkers to cognitive performance both before and after their procedures.Their findings are revealing fascinating insights about what makes some brains more resilient than others when faced with the significant stress of major surgery - insights that could help physicians better advise patients and potentially lead to interventions that enhance resilience.Read MoreUnder the Lights: What Surgery Reveals About Brain Resilience (Knight Initiative for Brain Resilience, 2025)Infusion of young donor plasma components in older patients modifies the immune and inflammatory response to surgical tissue injury: a randomized clinical trial (Journal of Translational Medicine, 2025)Blood test predicts recovery after hip-replacement surgery, study finds (Stanford Medicine, 2021)Can major surgery increase risk for Alzheimer's disease? (Stanford Medicine, 2021)Plasma Biomarkers of Tau and Neurodegeneration During Major Cardiac and Noncardiac Surgery (JAMA Neurology, 2021)Episode CreditsThis episode was produced by Michael Osborne at 14th Street Studios, with sound design by Morgan Honaker. Our logo is by Aimee Garza. The show is hosted by Nicholas Weiler at Stanford's Wu Tsai Neurosciences Institute and supported in part by the Knight Iniative for Brain Resilience.Get in touchWe want to hear from your neurons! Email us at at neuronspodcast@stanford.eduSend us a text!Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience. Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.

JCO PO author Dr. Dean A. Regier at the Academy of Translational Medicine, University of British Columbia (UBC), and the School of Population and Public Health, BC Cancer Research Institute shares insights into his JCO PO article, “Clinical Effectiveness and Cost-Effectiveness of Multigene Panel Sequencing in Advanced Melanoma: A Population-Level Real-World Target Trial Emulation.” Host Dr. Rafeh Naqash and Dr. Regier discuss the real-world clinical effectiveness and cost-effectiveness of multigene panels compared with single-gene BRAF testing to guide therapeutic decisions in advanced melanoma. Transcript Dr. Rafeh Naqash:Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, Podcast Editor for JCO Precision Oncology and Assistant Professor at the OU Health Stephenson Cancer Center in the University of Oklahoma. Today, we are excited to be joined by Dr. Dean A. Regier, Director at the Academy of Translational Medicine, Associate Professor at the School of Population and Public Health, UBC Senior Scientist at the British Columbia Cancer Research Institute, and also the senior author of the JCO Precision Oncology article entitled "Clinical Effectiveness and Cost-Effectiveness of Multigene Panel Sequencing in Advanced Melanoma: A Population-Level Real-World Target Trial Emulation." At the time of this recording, our guest's disclosures will be linked in the transcript. Dean, welcome to our podcast and thank you for joining us today. Dr. Dean Regier:Thank you. I'm delighted to be here. Dr. Rafeh Naqash:So, obviously, you are from Canada, and medicine, or approvals of drugs to some extent, and in fact approvals of gene testing to some extent is slightly different, which we'll come to learn about more today, compared to what we do in the US—and in fact, similarly, Europe versus North America to a large extent as well. Most of the time, we end up talking about gene testing in lung cancer. There is a lot of data, a lot of papers around single-gene panel testing in non-small cell lung cancer versus multigene testing. In fact, a couple of those papers have been published in JCO PO, and it has shown significant cost-effectiveness and benefit and outcomes benefit in terms of multigene testing. So this is slightly, you know, on a similar approach, but in a different tumor type. So, could you tell us first why you wanted to investigate this question? What was the background to investigating this question? And given your expertise in health economics and policy, what are some of the aspects that one tends or should tend to understand in terms of cost-effectiveness before we go into the results for this very interesting manuscript? Dr. Dean Regier:Yeah, of course, delighted to. So, one of the reasons why we're deeply interested in looking at comparative outcomes with respect to single- versus multigene testing— whether that's in a public payer system like Canada or an insurer system, a private system in the United States— is that the question around does multigene versus single-gene testing work, has not typically tested in randomized controlled trials. You don't have people randomized to multigene versus single-gene testing. And what that does, it makes the resulting evidence base, whether it's efficacy, safety, or comparative cost-effectiveness, highly uncertain. So, the consequence of that has been uneven uptake around the world of next-generation sequencing panels. And so if we believe that next-gen sequencing panels are indeed effective for our patients, we really need to generate that comparative evidence around effectiveness and cost-effectiveness. So we can go to payers, whether it be single payer or a private insurer, to say, "Here are the comparative outcomes." And when I say that uptake has been uneven, uptake there's been actually plenty, as you know, publications around that uneven uptake, whether it be in Europe, in the United States, in Canada. And so we're really interested in trying to produce that evidence to create the type of deliberations that are needed to have these types of technologies accessible to patients. And part of those deliberations, of course, is the clinical, but also in some contexts, cost-effectiveness. And so, we really start from the perspective of, can we use our healthcare system data, our learning healthcare system, to generate that evidence in a way that emulates a randomized controlled trial? We won't be able to do these randomized controlled trials for various, like really important and and reasons that make sense, quite frankly. So how can we mimic or emulate randomized controlled trials in a way that allows us to make inference around those outcomes? And for my research lab, we usually think through how do we do causal inference to address some of those biases that are inherent in observational data. So in terms of advanced melanoma, we were really interested in this question because first of all, there have been no randomized controlled trials around next-gen sequencing versus single-gene testing. And secondly, these products, these ICIs, immune checkpoint inhibitors, and BRAF and MEK inhibitors, they are quite expensive. And so the question really becomes: are they effective? And if so, to what extent are they cost-effective? Do they provide a good reason to have information around value for money? Dr. Rafeh Naqash:So now going to the biology of melanoma, so we know that BRAF is one of the tumor-agnostic therapies, it has approvals for melanoma as well as several other tumor types. And in fact, I do trials with different RAF-RAS kinase inhibitors. Now, one of the things that I do know is, and I'm sure some of the listeners know, is the DREAMseq trial, which was a melanoma study that was an NCI Cooperative Group trial that was led by Dr. Mike Atkins from Georgetown a couple of years back, that did show survival benefit of first-line immunotherapy sequencing. It was a sequencing study of whether to do first-line BRAF in BRAF-mutant melanoma followed by checkpoint inhibitors, or vice versa. And the immune checkpoint inhibitors followed by BRAF was actually the one that showed benefit, and the trial had to stop early, was stopped early because of the significant benefit seen. So in that context, before we approach the question of single-gene versus multigene testing in melanoma, one would imagine that it's already established that upfront nivolumab plus ipilimumab, for that matter, doublet checkpoint inhibitor therapy is better for BRAF-mutant melanoma. And then there's no significant other approvals for melanoma for NRAS or KIT, you know, mucosal melanomas tend to have KIT mutations, for example, or uveal melanomas, for that matter, have GNAQ, and there's no targeted therapies. So, what is the actual need of doing a broader testing versus just testing for BRAF? So just trying to understand when you started looking into this question, I'm sure you kind of thought about some of these concepts before you delved into that. Dr. Dean Regier:I think that is an excellent question, and it is a question that we asked ourselves: did we really expect any differences in outcomes between the testing strategies? And what did the real-world implementation, physician-guided, physician-led implementation look like? And so, that was kind of one of the other reasons that we really were interested is, why would we go to expanded multigene panel sequencing at all? We didn't really expect or I didn't expect an overall survival a priori. But what we saw in our healthcare system, what happened in our healthcare system was the implementation in 2016 of this multigene panel. And this panel covered advanced melanoma, and this panel cost quite a bit more than what they were doing in terms of the single-gene BRAF testing. And so when you're a healthcare system, you have to ask yourself those questions of what is the additional value associated with that? And indeed, I think in a healthcare system, we have to be really aware that we do not actually follow to the ideal extent randomized controlled trials or trial settings. And so that's the other thing that we have to keep in mind is when these, whether it's an ICI or a BRAF MEK inhibitor, when these are implemented, they do not look like randomized controlled trials. And so, we really wanted to emulate not just a randomized controlled trial, but a pragmatic randomized controlled trial to really answer those real-world questions around implementation that are so important to decision making. Dr. Rafeh Naqash:Sure. And just to understand this a little better: for us in the United States, when we talk about multigene testing, we generally refer to, these days, whole-exome sequencing with whole-transcriptome sequencing, which is like the nuclear option of of the testings, which is not necessarily cheap. So, when you talk about multigene testing in your healthcare system, what does that look like? Is it a 16-gene panel? Is it a 52-gene panel? What is the actual makeup of that platform? Dr. Dean Regier:Excellent question. Yeah, so at the time that this study is looking at, it was 2016, when we, as BC Cancer—so British Columbia is a population right now of 5.7 million people, and we have data on all those individuals. We are one healthcare system providing health care to 5.7 million people. In 2016, we had what I call our "home-brew" multigene panel, which was a 53-gene panel that was reimbursed as standard of care across advanced cancers, one of them being advanced melanoma. We have evolved since then. I believe in 2022, we are using one of the Illumina panels, the Focus panel. And so things have changed; it's an evolving landscape. But we're specifically focused on the 53-gene panel. It was called OncoPanel. And that was produced in British Columbia through the Genome Sciences Centre, and it was validated in a single-arm trial mostly around validity, etc. Dr. Rafeh Naqash:Thank you for explaining that. So now, onto the actual meat and the science of this project. So, what are some of the metrics from a health economy standpoint that you did look at? And then, methodology-wise, I understand, in the United States, we have a fragmented healthcare system. I have data only from my institution, for that matter. So we have to reach out to outside collaborators and email them to get the data. And that is different for you where you have access to all the data under one umbrella. So could you speak to that a little bit and how that's an advantage for this kind of research especially? Dr. Dean Regier:Yeah. In health economics, we look at the comparative incremental costs against the incremental effectiveness. And when we think about incremental costs, we think not just about systemic therapy or whether you see a physician, but also about hospitalizations, about all the healthcare interactions related to oncology or not that a patient might experience during their time or interactions with the healthcare system. You can imagine with oncology, there are multiple interactions over a prolonged time period depending on survival. And so what we try to do is we try to—and the benefit of the single-payer healthcare system is what we do is we link all those resource utilization patterns that each patient encounters, and we know the price of that encounter. And we compare those incremental costs of, in this case, it's the multigene panel versus the single-gene panel. So it's not just the cost of the panel, not just the cost of systemic therapy, but hospitalizations, physician encounters, etc. And then similarly, we look at, in this case, we looked at overall survival - we can also look at progression-free survival - and ask the simple question, you know, what is the incremental cost per life-year gained? And in that way, we get a metric or an understanding of value for money. And how we evaluate that within a deliberative priority setting context is we look at safety and efficacy first. So a regulatory package that you might get from, in our case, Health Canada or the FDA, so we look at that package, and we deliberate on, okay, is it safe and is it effective? How many patients are affected, etc. And then separately, what is the cost-effectiveness? And at what price, if it's not cost-effective, at what price would it be cost-effective? Okay, so for example, we have this metric called the incremental cost-effectiveness ratio, which is incremental cost in the numerator, and in this case, life-years gained in the denominator. And if it is around $50,000 or $100,000 per life-year gained—so if it's in that range, this ratio—then we might say it's cost-effective. If it's above this range, which is common in oncology, especially when we talk about ICIs, etc., then you might want to negotiate a price. And indeed, when we negotiate that price, we use the economic evaluation, that incremental cost-effectiveness ratio, as a way to understand at what price should we negotiate to in order to get value for money for the healthcare system. Dr. Rafeh Naqash:Thank you for explaining those very interesting terminologies. Now, one question I have in the context of what you just mentioned is, you know, like the drug development space, you talked about efficacy and safety, but then on the safety side, we talk about all-grade adverse events or treatment-related adverse events—two different terminologies. From a healthcare utilization perspective, how do you untangle if a patient on a BRAF therapy got admitted for a hypoxic respiratory failure due to COPD, resulting in a hospitalization from the cost, overall cost utilization, or does it not matter? Dr. Dean Regier:We try to do as much digging into those questions as possible. And so, this is real-world data, right? Real-world data is not exactly as clean as you'd get from a well-conducted clinical trial. And so what we do is we look at potential adverse event, whether it's hospitalization, and the types of therapies around that hospitalization to try- and then engage with clinicians to try to understand or tease out the different grades of the adverse event. Whether it's successful or not, I think that is a real question that we grapple with in terms of are we accurate in delineating different levels of adverse events? But we try to take the data around the event to try to understand the context in which it happens. Dr. Rafeh Naqash:Thank you for explaining that, Dean. So, again to the results of this manuscript, could you go into the methodology briefly? Believe you had 147 patients, 147 patients in one arm, 147 in the other. How did you split that cohort, and what were some of the characteristics of this cohort? Dr. Dean Regier:So, the idea, of course, is that we have selection criteria, study inclusion criteria, which included in our case 364 patients. And these were patients who had advanced melanoma within our study time period. So that was 2016 to 2018. And we had one additional year follow. So we had three total years. And what we did is that we linked our data, our healthcare system data. During this time, because the policy change was in 2016, we had patients both go on the multigene panel and on the single-gene BRAF testing. So, the idea was to emulate a pragmatic randomized controlled trial where we looked at contemporaneous patients who had multigene panel testing versus single-gene BRAF testing. And then we did a matching procedure—we call it genetic matching. And that is a type of matching that allows us to balance covariates across the patient groups, across the multigene versus BRAF testing cohorts. The idea again is, as you get in a randomized controlled trial, you have these baseline characteristics that look the same. And then the hope is that you address any source selection or confounding biases that prohibit you to have a clean answer to the question: Is it effective or cost-effective? So you address all those biases that may prohibit you to find a signal if indeed a signal is there. And so, what we did is we created—we did this genetic matching to balance covariates across the two cohorts, and we matched them one-to-one. And so what we were able to do is we were able to find, of those 364 patients in our pool, 147 in the multigene versus 147 in the single-gene BRAF testing that were very, very similar. In fact, we created what's called a directed acyclic graph or a DAG, together with clinicians to say, “Hey, what biases would you expect to have in these two cohorts that might limit our ability to find a signal of effectiveness?” And so we worked with clinicians, with health economists, with epidemiologists to really understand those different biases at play. And the genetic matching was able to match the cohorts on the covariates of interest. Dr. Rafeh Naqash:And then could you speak on some of the highlights from the results? I know you did survival analysis, cost-effectiveness, could you explain that in terms of what you found? Dr. Dean Regier:We did two analyses. The intention-to-treat analysis is meant to emulate the pragmatic randomized controlled trial. And what that does is it answers the question, for all those eligible for multigene or single-gene testing: What is the cost-effectiveness in terms of incremental life-years gained and incremental cost per life-years gained? And the second one was around a protocol analysis, which really answered the question of: For those patients who were actually treated, what was the incremental effectiveness and cost-effectiveness? Now, they're different in two very important ways. For the intention-to-treat, it's around population questions. If we gave single-gene or multigene to the entire population of advanced melanoma patients, what is the cost-effectiveness? The per-protocol is really around that clinical question of those who actually received treatment, what was the incremental cost and effectiveness? So very different questions in terms of population versus clinical cost and effectiveness. So, for the intention-to-treat, what we found is that in terms of life-years gained is around 0.22, which is around 2.5 months of additional life that is afforded to patients who went through the multigene panel testing versus the single-gene testing. That was non-statistically significant from zero at the 5% level. But on average, you would expect this additional 2.5 months of life. The incremental costs were again non-statistically significant, but they're around $20,000. And so when we look at incremental cost-effectiveness, we can also look at the uncertainty around that question, meaning what percentage of incremental cost-effectiveness estimates are likely to be cost-effective at different willingness-to-pay thresholds? Okay? So if you are willing to pay $100,000 to get one gain of life-years, around 52.8% of our estimates, in terms of when we looked at the entire uncertainty, would be cost-effective. So actually that meets the threshold of implementation in our healthcare system. So it's quite uncertain, just over 50%. But what we see is that decision-makers actually have a high tolerance for uncertainty around cost-effectiveness. And so, while it is uncertain, we would say that, well, the cost-effectiveness is finely balanced. Now, when we looked at the population, the per-protocol population, those folks who just got treatment, we actually have a different story. We have all of a sudden around 4.5 or just under 5 months of life gained that is statistically significantly different from zero, meaning that this is a strong signal of benefit in terms of life-years gained. In terms of the changes in costs or the incremental costs, they are larger again, but statistically insignificant. So the question now is, to what extent is it cost-effective? What is the probability of it being cost-effective? And at the $100,000 per life-year gained willingness-to-pay, there was a 73% chance that multigene panel testing versus single-gene testing is cost-effective. Dr. Rafeh Naqash:So one of the questions I have here, this is a clarification both for myself and maybe the listeners also. So protocol treatment is basically if you had gene testing and you have a BRAF in the multigene panel, then the patient went on a BRAF treatment. Is that correct? Dr. Dean Regier:It's still physician choice. And I think that's important to say that. So typically what we saw in both in our pre- and post-matching data is that we saw around 50% of patients, irrespective of BRAF status, get an ICI, which is appropriate, right? And so the idea here is that you get physician-guided care, but if the patient no longer performs on the ICI, then it gives them a little bit more information on what to do next. Even during that time when we thought it wasn't going to be common to do an ICI, but it was actually quite common. Dr. Rafeh Naqash:Now, did you have any patients in this study who had the multigene testing done and had an NRAS or a KIT mutation and then went on to those therapies, which were not captured obviously in the single-gene testing, which would have just tried to look at BRAF? Dr. Dean Regier:So I did look at the data this morning because I thought that might come up in terms of my own questions that I had. I couldn't find it, but what we did see is that some patients went on to clinical trials. So, meaning that this multigene panel testing allowed, as you would hope in a learning healthcare system, patients to move on to clinical trials to have a better chance at more appropriate care if a target therapy was available. Dr. Rafeh Naqash:And the other question in that context, which is not necessarily related to the gene platform, but more on the variant allele frequency, so if you had a multigene panel that captured something that was present at a high VAF, with suspicion that this could be germline, did you have any of those patients? I'm guessing if you did, probably very low number, but I'm just thinking from a cost-effective standpoint, if you identify somebody with germline, their, you know, first-degree relative gets tested, that ends up, you know, prevention, etc. rather than somebody actually developing cancer subsequently. That's a lot of financial gains to the system if you capture something early. So did you look at that or maybe you're planning to look at that? Dr. Dean Regier:We did not look at that, but that is a really important question that typically goes unanswered in economic evaluations. And so, the short answer is yes, that result, if there was a germline finding, would be returned to the patient, and then the family would be able to be eligible for screening in the appropriate context. What we have found in economic evaluations, and we've recently published this research, is that that scope of analysis is rarely incorporated into the economic evaluation. So those downstream costs and those downstream benefits are ignored. And when you- especially also when you think about things like secondary or incidental findings, right? So it could be a germline finding for cancer, but what about all those other findings that we might have if you go with an exome or if you go with a genome, which by the way, we do have in British Columbia—we do whole-genome and transcriptome sequencing through something called the Personalized OncoGenomics program. That scope of evaluation, because it's very hard to get the right types of data, because it requires a decision model over the lifetime of both the patients and potentially their family, it becomes very complicated or complex to model over patients' and families' lifetime. That doesn't mean that we should not do it, however. Dr. Rafeh Naqash:So, in summary Dean, could you summarize some of the known and unknowns of what you learned and what you're planning in subsequent steps to this project? Dr. Dean Regier:Our North Star, if you will, is to really understand the entire system effect of next-generation sequencing panels, exome sequencing, whole genomes, or whole genomes and transcriptome analysis, which we think should be the future of precision oncology. The next steps in our research is to provide a nice base around multigene panels in terms of multigene versus single-gene testing, whether that be colorectal cancer, lung cancer, melanoma, etc., and to map out the entire system implications of implementing next-generation sequencing panels. And then we want to answer the questions around, “Well, what if we do exomes for all patients? What if we do whole genomes and transcriptomes for all patients? What are the comparative outcomes for a true tumor-agnostic precision oncology approach, accounting for, as you say, things like return of results with respect to hereditary cancers?” I think the challenge that's going to be encountered is really around the persistent high costs of something like a whole-genome and transcriptome sequencing approach. Although we do see the technology prices going down—the "$1,000 genome" or “$6,000 genome" on whatever Illumina machine you might have—that bioinformatics is continuing to be expensive. And so, there are pipelines that are automated, of course, and you can create a targeted gene report really rapidly within a reasonable turnaround time. But of course, for secondary or what I call level two analysis, that bioinformatics is going to continue to be expensive. And so, we're just continually asking that question is: In our healthcare system and in other healthcare systems, if you want to take a precision oncology approach, how do you create the pipelines? And what types of technologies really lend themselves to benefits over and above next-generation sequencing or multigene panels, allowing for access to off-label therapies? What does that look like? Does that actually improve patients? I think some of the challenges, of course, is because of heterogeneity, small benefiting populations, finding a signal if a signal is indeed there is really challenging. And so, what we are thinking through is, with respect to real-world evidence methods and emulating randomized controlled trials, what types of evidence methods actually allow us to find those signals if indeed those signals are there in the context of small benefiting populations? Dr. Rafeh Naqash:Thank you so much, Dean. Sounds like a very exciting field, especially in the current day and age where cost-effectiveness, financial toxicity is an important aspect of how we improve upon what is existing in oncology. And then lots more to be explored, as you mentioned. The last minute and a half I want to ask about you as an individual, as a researcher. There's very few people who have expertise in oncology, biomarkers, and health economics. So could you tell us for the sake of our trainees and early career physicians who might be listening, what was your trajectory briefly? How did you end up doing what you're doing? And maybe some advice for people who are interested in the cost of care, the cost of oncology drugs - what would your advice be for them very briefly? Dr. Dean Regier:Sure. So I'm an economist by training, and indeed I knew very little about the healthcare system and how it works. But I was recruited at one point to BC Cancer, to British Columbia, to really try to understand some of those questions around costs, and then I learned also around cost-effectiveness. And so, I did training in Scotland to understand patient preferences and patient values around quality of care, not just quantity of life, but also their quality of life and how that care was provided to them. And then after that, I was at Oxford University at the Nuffield Department of Population Health to understand how that can be incorporated into randomized control trials in children. And so, I did a little bit of learning about RCTs. Of course, during the way I picked up some epidemiology with deep understanding of what I call econometrics, what others might call biostatistics or just statistics. And from there, it was about working with clinicians, working with epidemiologists, working with clinical trialists, working with economists to understand the different approaches or ways of thinking of how to estimate efficacy, effectiveness, safety, and cost-effectiveness. I think this is really important to think through is that we have clinical trialists, we have people with deep understanding of biostatistics, we have genome scientists, we have clinicians, and then you add economists into the mix. What I've really benefited from is that interdisciplinary experience, meaning that when I talk to some of the world's leading genome scientists, I understand where they're coming from, what their hope and vision is. And they start to understand where I'm coming from and some of the tools that I use to understand comparative effectiveness and cost-effectiveness. And then we work together to actually change our methods in order to answer those questions that we're passionate about and curious about better for the benefit of patients. So, the short answer is it's been actually quite a trajectory between Canada, the UK. I spent some time at the University of Washington looking at the Fred Hutch Cancer Research Center, looking at precision oncology. And along the way, it's been an experience about interdisciplinary research approaches to evaluating comparative outcomes. And also really thinking through not just at one point in time on-off decisions—is this effective? Is it safe? Is it cost-effective?—not those on-off decisions, but those decisions across the lifecycle of a health product. What do those look like at each point in time? Because we gain new evidence, new information at each point in time as patients have more and more experience around it. And so what really is kind of driving our research is really thinking about interdisciplinary approaches to lifecycle evaluation of promising new drugs with the goal of having these promising technologies to patients sooner in a way that is sustainable for the healthcare system. Dr. Rafeh Naqash:Awesome. Thank you so much for those insights and also giving us a sneak peek of your very successful career. Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review, and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcast. Thank you. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.      

Medical science is advancing at an astonishing rate. Today we talk with leading expert Eric Topol about two aspects of this story. First, the use of artificial intelligence in medicine, especially in diagnostics. This is an area that is a perfect match between an important question and the capabilities of machine learning, to the point where AI can out-perform human doctors. And second, our understanding of aging and what to do about it. Eric even gives some actionable advice on how to live more healthily into our golden years.Blog post with transcript: https://www.preposterousuniverse.com/podcast/2025/05/05/episode-313-eric-topol-on-the-changing-face-of-medicine-and-aging/Support Mindscape on Patreon.Eric Topol received and M.D. from the University of Rochester. He is currently the Gary and Mary West Chair of Innovative Medicine in the Department of Translational Medicine at Scripps Research. He is also the Founder, Scripps Research Translational Institute, and Senior Consultant, Scripps Clinic, Division of Cardiovascular Diseases. Among his awards are the Hutchinson Medal from the University of Rochester and membership in the National Academy of Sciences. His books include Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again, and Super Agers: An Evidence-Based Approach to Longevity.Web siteScripps web pageGoogle Scholar publicationsWikipediaSubstackBlueskySee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us a textDr. Peter Ordentlich, Ph.D. is Chief Scientific Officer and Founder, Syndax Pharmaceuticals ( https://syndax.com/team/peter-ordentlich-ph-d/ ), a company with a mission to obtain regulatory approval and commercialize drugs that extend and improve the lives of cancer patients, by drawing on the newest scientific research and advances, collaborating with determined problem solvers, and identifying value in overlooked aspects of science.Dr. Ordentlich co-founded the Company in October 2005 and has served as Chief Scientific Officer since September 2016.Dr. Ordentlich previously served as Syndax's Chief Technical Officer, Vice President, Translational Medicine, Executive Director, Translational Science, and Director, Scientific Affairs and Strategic Alliances.Prior to founding the company, Dr. Ordentlich was a scientist at the Salk Institute for Biological Studies, a biological research non-profit organization. He also spent five years as a research scientist at X-Ceptor Therapeutics, Inc., a drug discovery company, which was acquired by Exelixis, Inc.Dr. Ordentlich received a B.A. in Biochemistry and a Ph.D. in Immunology from the University of Pennsylvania.#PeterOrdentlich #SyndaxPharmaceuticals #Oncology #Cancer #Menin #KMT2Ar #AcuteLeukemias #NPM1m #AcuteMyeloidLeukemia #Revuforj #Niktimvo #Axatilimab #Revumenib #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcast #STEM #Innovation #Science #Technology #ResearchSupport the show

Commentary by Dr. Jian'an Wang.

Send us a textJoin Marla Dalton, PE, CAE, and William Schaffner, MD, for a fascinating conversation with cardiologist and renowned biomedical researcher Eric Topol, MD, on the revolutionary impact of artificial intelligence (AI) in medicine and healthcare. Topol shares how AI can help strengthen the patient-doctor relationship, enhance diagnostics, and reduce medical errors.Show notesA practicing cardiologist, Topol is chair and professor of Translational Medicine at Scripps Research. One of the most cited researchers in medicine, he has published several bestselling books on the future of medicine, including a new book that explores research transforming human longevity and chronic disease. He was elected to the National Academy of Medicine and was commissioned to lead a review of the UK National Health Service. Additionally, he is the editor-in-chief of Medscape and publishes the Substack newsletter, Ground Truths. Known for his groundbreaking studies on AI in medicine, genomics, and digitized clinical trials, Topol was named to the TIME100 Health list of the most influential people in health in 2024.  Follow NFID on social media

This important webinar is designed to equip health professionals and leaders with the tools, insights, and strategies to foster mental wellbeing in their teams during crises and beyond. This session will:* Present key research findings on healthcare workers' mental health needs during crises like COVID-19.* Introduce an insightful report and checklist as actionable resources for enhancing mental health support in healthcare settings.* Demonstrate how addressing mental health can strengthen teams and improve organisational outcomes.* Use compelling data to outline what needs to change and the steps leaders can take to drive improvement.* Empower healthcare leaders with clear, implementable recommendations for creating mentally healthy workplaces. Facilitator: Dr Peter Baldwin – Senior Research Fellow and Clinical Psychologist, Black Dog Institute | Co- Investigator, Future-Proofing the Frontline guide Panellists: Prof Natasha Smallwood – Respiratory Physician, Department of Respiratory & Sleep Medicine at The Alfred Hospital; Head Chronic Respiratory Disease Group and Respiratory Research Training Lead                                          Respiratory Research @ The Alfred School of Translational Medicine, Monash University; and Chief Investigator, Future-Proofing the Frontline report Dr Bethan Richards – Chief Medical Wellness Officer / Director SLHD MDOK Centre | Rheumatologist, Co- Director Institute for Musculoskeletal Health, PhD Health ProfessionalJess Maher- Lived Experience Representative, endorsed enrolled nurse                 Future-Proofing the Frontline: Organisational strategies to support frontline healthcare workers and leaders during times of crisis, is a guide that brings together insights from diverse perspectives and multiple sources of data to understand the best organisational strategies for supporting the mental health of healthcare workers. The guide and Organisational Checklist are available here: https://www.blackdoginstitute.org.au/news/future-proofing-the-frontline/

This important webinar is designed to equip health professionals and leaders with the tools, insights, and strategies to foster mental wellbeing in their teams during crises and beyond. This session will:* Present key research findings on healthcare workers' mental health needs during crises like COVID-19.* Introduce an insightful report and checklist as actionable resources for enhancing mental health support in healthcare settings.* Demonstrate how addressing mental health can strengthen teams and improve organisational outcomes.* Use compelling data to outline what needs to change and the steps leaders can take to drive improvement.* Empower healthcare leaders with clear, implementable recommendations for creating mentally healthy workplaces. Facilitator: Dr Peter Baldwin – Senior Research Fellow and Clinical Psychologist, Black Dog Institute | Co- Investigator, Future-Proofing the Frontline guide Panellists: Prof Natasha Smallwood – Respiratory Physician, Department of Respiratory & Sleep Medicine at The Alfred Hospital; Head Chronic Respiratory Disease Group and Respiratory Research Training Lead                                          Respiratory Research @ The Alfred School of Translational Medicine, Monash University; and Chief Investigator, Future-Proofing the Frontline report Dr Bethan Richards – Chief Medical Wellness Officer / Director SLHD MDOK Centre | Rheumatologist, Co- Director Institute for Musculoskeletal Health, PhD Health ProfessionalJess Maher- Lived Experience Representative, endorsed enrolled nurse                 Future-Proofing the Frontline: Organisational strategies to support frontline healthcare workers and leaders during times of crisis, is a guide that brings together insights from diverse perspectives and multiple sources of data to understand the best organisational strategies for supporting the mental health of healthcare workers. The guide and Organisational Checklist are available here: https://www.blackdoginstitute.org.au/news/future-proofing-the-frontline/

In this episode, Ayesha spoke with Lee Honigberg, PhD, VP of Research & Development, ALZpath, a provider of diagnostic tools for Alzheimer's disease.    This includes a blood-based biomarker assay, called the ALZpathDx assay, which measures pTau217 in the blood. Prior to joining ALZpath, Dr. Honigberg was most recently Senior Director and Distinguished Scientist in Translational Medicine at Genentech, where he was leading a group responsible for biomarker development for programs in neuroscience, ophthalmology, cardiovascular and metabolic disease. Before Genentech, Dr. Honigberg was at Pharmacyclics where he led the preclinical development of ibrutinib, the first approved BTK inhibitor, establishing a new standard of treatment in chronic lymphocytic leukemia (CLL). Dr. Honigberg's contributions were recognized by the 2019 ACS Heroes in Chemistry award. Dr. Honigberg received a PhD in Neuroscience from the University California San Francisco (UCSF). Tune into to the episode to learn about the latest innovations in Alzheimer's diagnostics. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

What if we could target cancer at its metabolic core? In this episode of The Metabolic Link, Dr. Dominic D'Agostino is joined by Dr. Tomás Duraj, a physician and cancer metabolism researcher working alongside Dr. Thomas Seyfried.Dr. Duraj is the lead author of a groundbreaking review on ketogenic metabolic therapy for glioblastoma, bringing together leading experts to explore how metabolic strategies could reshape cancer treatment.In this deep-dive conversation, they discuss the bioenergetics of cancer, the role of mitochondria, the Warburg effect, and why targeting glucose and glutamine metabolism may be the key to making standard cancer therapies more effective.Whether you're a researcher, clinician, or someone interested in the latest advancements in cancer therapy, this episode is packed with insights that could redefine the way we think about cancer treatment. Watch the full episode here or listen on your favorite podcast player for this must-hear discussion on the future of metabolic therapy for cancer!Read Dr. Duraj's paper: Clinical research framework proposal for ketogenic metabolic therapy in glioblastomaAbout Dr. Tomás DurajDr. Tomás Duraj is a Czech physician-scientist, receiving his Medical Degree from the Rey Juan Carlos University and his PhD in Translational Medicine from the CEU San Pablo University (Madrid, Spain). His research focuses on studying the potential of bioenergetic modulation in cancer metabolism, with special emphasis on glioblastoma, the most aggressive and lethal primary brain tumor. After developing cancer research at the team of Dr. Ayuso Sacido, he joined Dr. Thomas N. Seyfried's laboratory in Boston College. His goal is to advance our understanding of metabolic oncology on a rigorous, evidence-based background, making it part of the standard oncology toolkit.Special thanks to the sponsors of this episode:Puori: Get 20% off Puori supplements at https://puori.com/METABOLICLINK and use the code METABOLICLINKFatty15: Get an additional 15% off their 90-day subscription Starter Kit by going to https://fatty15.com/METABOLICLINK and use code METABOLICLINK.MUDWTR: Get up to 43% off with code METABOLICLINK at https://mudwtr.com/METABOLICLINKIn every episode of The Metabolic Link, we'll uncover the very latest research on metabolic health and therapy. If you like this episode, please share it, subscribe, follow, and leave us a comment or review on whichever platform you use to tune in!You can find us on all your major podcast players here and full episodes are also up on our Metabolic Health Summit YouTube channel!Find us on social: Instagram Facebook YouTube LinkedIn Please keep in mind: The Metabolic Link does not provide medical or health advice, but rather general information that does not serve as a substitute for a licensed healthcare professional. Never delay in seeking medical advice from an appropriately licensed medical provider for any health condition that you may have.

Hosts: Dr Shane, Dr Suzie, Dr LindenNews Items: Rivers function in our world, intermittent fasting,1st guest: Dakota Rhys-Jones is a PhD student and Accredited Practicing Dietitian at Monash University's Department of Gastroenterology, School of Translational Medicine, The Alfred Centre. Dakota's PhD focuses on the role of diet in inflammatory bowel disease, specifically patients with ulcerative colitis who then go onto getting their large intestine removed and the formation of an ileoanal pouch. Patients with a pouch have the last part of their small intestine sewn to their anus so that they can defecate normally, and although the diseased colon is removed, problems can arise, such as inflammation of the pouch. We know that diet plays a role in IBD, but knowledge around diet and pouches is limited, so patients and clinicians are left at a bit of a loss when discussing diet.2nd guest: Dr Natalia Sampaio from the Hudson Institute on auto inflammatory and rare inherited diseases.Thank you and farewell to Dr Linden!Program page: Einstein-A-Go-GoFacebook page: Einstein-A-Go-GoX: Einstein-A-Go-Go

Part 2 of 4: Jon Chee hosts Barry Ticho, Founder of Verve Therapeutics and Chief Medical Officer at Stoke Therapeutics, a biotech company addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. With an MD-PhD from the University of Chicago and extensive experience across academia and industry, Barry brings over two decades of expertise in clinical development. His journey includes roles as Head of Development at Moderna, Head of External R&D Innovation at Pfizer, and VP of Clinical Development at Biogen, where he's been instrumental in advancing numerous therapeutic programs across multiple disease areas. Barry's unique perspective spanning academic medicine and biotechnology innovation makes his insights invaluable for aspiring leaders in the field.

Estudo publicado no Clinical and Translational Medicine revela que extracto de cogumelo branco tem propriedades anti cancerigenas tanto a nível profilático como terapeutico

Estudo publicado no Journal of Translational Medicine concluiu que apps com chatbots de IA, como a Replika ou a Anima, combatem efectivamente a solidão e os seus efeitos mantêm-se durante vários dias

Each year, approximately 230,000 Canadians, or 1 in 100, receive ICU care. While over 90% survive, up to 55% of survivors develop long-lasting cognitive impairment within two years of ICU discharge. Recent research suggests that inadequate blood flow to the brain may play a role. The purpose of Jiale’s research is to identify patients' optimal blood pressure ranges in real-time in the ICU and explore the feasibility of maintaining them within these ranges using clinically available blood pressure infusions. For upcoming interviews check out the Grad Chat webpage on Queen’s University School of Graduate Studies & Postdoctoral Affairs website

Does magnesium supplementation reduce muscle soreness across various physical activities?a review paper published in the Journal of Translational Medicine explored the effects of magnesium supplementation on muscle soreness across different physical activities.Findings:*Reduction in muscle soreness: magnesium significantly reduced muscle soreness and improves feelings of recovery in subjects.*Performance enhancement: positive effects on performance metrics, including improved blood glucose levels and reduced muscle damage markers.*Protective effects: regular magnesium intake showed a protective effect on muscle integrity during intense physical activities, such as professional cycling and team sports.Dosage and timing: The review suggests that individuals engaged in intense physical activities should consider a magnesium dosage 10-20% higher than the Recommended Dietary Allowance (RDA), ideally taken in capsule form 2 hours before training.  Of note, information regarding the effectiveness of this specific dose and time is very scarce. It was also advised to maintain magnesium levels within the recommended range during the off-season.Why magnesium is important for recovery: magnesium, an essential intracellular cation, is crucial for numerous biochemical reactions, including energy production, neuronal activity, cardiac function, and muscle contraction. Magnesium deficiency can impair physical performance and exacerbate muscle soreness post-exercise.What magnesium is best for muscle recovery: tissue distribution data would suggest magnesium citrate is best for muscle recovery. However, long-term magnesium intake far outweighs acute tissue distribution after a single dose of magnesium.What are magnesium-rich foods: Nuts and Seeds:Almonds: 80 mg per ounceCashews: 74 mg per ouncePumpkin Seeds: 150 mg per ounceChia Seeds: 95 mg per ounceFlaxseeds: 40 mg per tablespoonLeafy Greens:Spinach: 157 mg per cooked cupSwiss Chard: 150 mg per cooked cupKale: 30 mg per cooked cupLegumes:Black Beans: 120 mg per cooked cupLentils: 71 mg per cooked cupChickpeas: 78 mg per cooked cupEdamame: 99 mg per cooked cupWhole Grains:Quinoa: 118 mg per cooked cupBrown Rice: 86 mg per cooked cupOats: 61 mg per cooked cupBarley: 35 mg per cooked cupSources:PMID: 29637897PMID: 34111673PMID: 38970118Support the Show.

Hear from Barbara Ackerman, 72, lung cancer, Plymouth, with Pasi Jänne, MD, PhD, Senior Vice President for Translational Medicine, Dana-Farber Craig Bunnell, MD, Chief Medical Officer, Dana-Farber Kevin Haigis, PhD, Cancer Biology, Chief Scientific Officer, Dana-Farber  

Research scientists are equipping a vaccine with bits of proteins that redirect the immune system's efforts to specifically fight cancer. The vaccine aims to prevent cancer tumors from returning, as relapsing cancer is often more aggressive and difficult to treat. The latest research also seeks to understand why some cancer tumors evade the body's immune response. Featured experts are Dr. Keith Knutson, Immunologist and Cancer Vaccine Researcher at Mayo Clinic; Dr. Saranya Chumsri, Hematologist at Mayo Clinic​; and Dr. Nora Disis, Director of the Institute of Translational Health Science and the Center for Translational Medicine in Women's Health at University of Washington.

While multiple sclerosis (MS) has been traditionally described as a disease of young adults, the significant improvements in treatments over the past few decades has meant that researchers and clinicians are now increasingly handling questions related to the impact of ageing.  In this episode, host Brett Drummond of MSTranslate talks with Anneke Van Der Walt, Director of MS and Neuroimmunology and Neuro-ophthalmology at Alfred Health in Melbourne, Australia and lead of the MS and Neuro-ophthalmology Research Group at the School of Translational Medicine, Monash University; and Professor Frederik Barkhof, Chair of Neuroradiology, Brain Repair & Rehabilitation at University College London's Queen Square Institute of Neurology and Professor in Neuroradiology at the Department of Radiology & Nuclear Medicine at VUmc in Amsterdam, on the key takeaways from a recent international workshop on ageing.

Dublin-based FIRE1 today announced that the first Irish patient has been successfully implanted with its FIRE1 System for remote heart failure monitoring. The innovative system has the potential to positively impact thousands of people living with heart failure in Ireland every year and alleviate the burden on hospital emergency rooms. The successful implantation took place at University Hospital Galway in the First in Human Clinical Investigation of the FIRE1 System in Heart Failure Patients (FUTURE-HF). The study will assess FIRE1's novel solution to improve outcomes for those living with heart failure. Irish medtech company FIRE1, whose CEO, Conor Hanley, was recently announced as a 2024 EY Entrepreneur of the Year finalist, seeks to transform heart failure management by enabling patients to monitor and control their fluid volume themselves with a device at home, similar to how continuous glucose monitoring transformed diabetes care. Fluid overload is a classic clinical feature of heart failure, which affects approximately 90,000 Irish people and is a leading cause of hospitalisations, including high admission and re-admission rates in Ireland. FIRE1 CEO and President Conor Hanley said, "I am especially pleased to announce our first patient in Ireland. This represents a true clinical research success for Ireland, being one of the first systems of its nature to be developed, manufactured, and now in a clinical trial in Ireland. It showcases Ireland's capability for groundbreaking medical innovation with the potential to change healthcare delivery globally. The FIRE1 team is steadfast in our mission to help millions of people around the world living with heart failure to get their normal lives back, but it is very special to be able to give access to people here at home. It is gratifying to see the physician interest in our novel technology. I would like to extend my thanks on behalf of the whole FIRE1 team to the fantastic staff at UHG, and most importantly to the patients who continue to put their trust in us and participate in this important research." The FIRE1 sensor is implanted into the body's largest vein, located in the abdomen, known as the inferior vena cava (IVC) and works by continuously measuring the size of the IVC, giving a marker of the amount of fluid in the body. High levels can increase the risk of breathing difficulties and a build-up of fluid in the lungs, which lead to an emergency hospital admission. The patient wears a belt reader around the abdomen for around a minute a day to take a reading from the sensor and the data is sent to the patient's clinical team at the hospital. The system is designed to alert whenever the patient's condition deteriorates. Professor of Interventional Cardiology and Translational Medicine at University Hospital Galway (UHG), Prof Faisal Sharif performed the implant. "We are delighted to bring this new, transformative technology to Ireland for the first time," said Prof Sharif. "The procedure was very straightforward, minimally invasive and the patient was confident using the FIRE1 system and taking the readings. The data we will get from this patient will give a new window into heart failure management and has the potential to dramatically improve our understanding of this patient's condition, and to enable proactive changes in medications that will keep them healthy and at home. We hope to implant further patients at UHG while recruitment is still active."

How do you amplify an immune response, analyse an earthquake or explain your irrational rage at people's mouth noise? This week Dr Shane, Dr Susi, Dr Ray and Dr Graci dive in and discuss the latest technology for direct air capture carbon management, printable and eco-friendly sensors that can be ‘imperceptive-ly printed' for use as continuous health monitors, and misophonia: a new diagnosis of decreased tolerance to specific sounds (yes, 80% are linked to the mouth or nose). Dr Ali Dvorscek (School of Translational Medicine, Monash University) joins the show to speak about B cells: the clever cells that generate antibodies by recognising their target antigens. Plus, Adam Pascale (Chief Scientist at the Seismology Research Centre) explains why nowhere in the world is immune from the pressures of tectonic plates moving. It turns out Australia has loads of earthquakes, they're just smaller than in some other parts of the world. Phew.Program page: Einstein-A-Go-GoFacebook page: Einstein-A-Go-GoTwitter: Einstein-A-Go-Go

In this episode, Marcelle and Raimi talk with special guest and associate producer of the pod, Reese, about detransition and retransition. Following the previous episode's conversation on transition and autonomy, Reese shares their experience with de/re-transition and the trio discuss the fears, guilt and shame that make up the political and social ‘boogeyman' of detransition. If you enjoy this episode, please share it with family and friends! To learn how to sponsor an episode, head to ohwitchplease.com/sponsorships. And to help support the show for ZERO COST, leave us an Apple review and send the show to family and friends!***Citations:Defining Detransition MacKinnon, Kinnon Ross, Pablo Expósito-Campos, and W. Ariel Gould. "Detransition needs further understanding, not controversy." bmj 381 (2023).Physician Education and Fears:MacKinnon, Kinnon R., et al. "Preventing transition “regret”: An institutional ethnography of gender-affirming medical care assessment practices in Canada." Social Science & Medicine 291 (2021): 114477.Other Sources:Hall, R., Mitchell, L., & Sachdeva, J. (2021). Access to care and frequency of detransition among a cohort discharged by a UK national adult gender identity clinic: Retrospective case-note review. BJPsych Open, 7(6), e184.Hughes, Laine. "Wronging the right-body narrative: On the universality of gender uncertainty." Current critical debates in the field of transsexual studies. Routledge, 2018. 181-193.MacKinnon, Kinnon R., et al. "Health care experiences of patients discontinuing or reversing prior gender-affirming treatments." JAMA Network Open 5.7 (2022): e2224717-e2224717.Narayan, Sasha Karan, et al. "Guiding the conversation—types of regret after gender-affirming surgery and their associated etiologies." Annals of Translational Medicine 9.7 (2021).Turban, Jack L., et al. "Factors leading to “detransition” among transgender and gender diverse people in the United States: A mixed-methods analysis." LGBT health 8.4 (2021): 273-280.You can find more resources and research on the Gender Playground website at ohwitchplease.ca/gender-playground.***Gender Playground is a new show from Witch, Please Productions and is co-hosted by longtime friends Marcelle Kosman and Raimi Marx. This podcast is all about gender-affirming care for the kids in your life, and YOU are the intended audience! Whether you're a caregiver, parent, family-member, chosen-family-member, teacher, doctor, childcare professional, or just someone who wants to create a more loving world for kids, this show is for you! Hosted on Acast. See acast.com/privacy for more information.

Organ transplantation is a modern marvel, with more than 157,000 solid organ, and more than 9,000 marrow and blood transplants occurring worldwide in 2022. Organ donor and recipient matching and compatibility screening has progressed significantly in recent decades as molecular methods have progressed rapidly to support this and other fields. Specifically, typing of human leukocyte antigens (HLAs) has expanded to consider ethnic population variation and cell free DNA (cfDNA) monitoring is now being used to monitor recipients for biomarkers that indicate organ rejection.  Our guest for this episode, Dr. Lee Ann Baxter-Lowe, Director of the HLA Laboratory at Children's Hospital Los Angeles has been working in the field of transplantation science for virtually her entire career. Join us for a great explanation of the science and a first-hand recounting of developing the assays, from decades ago, before thermal cyclers existed, to her cutting-edge work using digital PCR to progress the field even further. Lee Ann also shares very personal aspects of her career journey in her conversation with Cassie. This includes her describing the scientific “studies” of her and her cousin as children, her venturing into the world of HLA typing when it was emerging, and the role her family has played in her career, which gets personal quickly when she shares that her husband is currently dealing with a blood malignancy. Visit the Absolute Gene-ius page to learn more about the guests, the hosts, and the Applied Biosystems QuantStudio Absolute Q Digital PCR System. 

Michael Charlton and the Surfers discuss two issues: defining therapeutic futility for Rezdiffra and describing some advances in MASLD translational medicine. The conversation starts by continuing the topic of therapeutic futility. Louise Campbell asks Michael how he plans to determine therapeutic futility with Rezdiffra in terms of side effects or efficacy. Michael indicates that he will continue patients on Rezdiffra as long as their disease does not progress. While he would prefer a more robust approach, he describes the scale of challenge in defining futility for a drug where FibroScan and transaminase levels did not provide strong prediction.Roger Green asks what percentage of patients are taking concomitant GLP-1 therapy. This leads to a brief sideline discussion on levels of therapeutic adherence.Roger asks Michael what he find exciting in translational medicine these days. Michael cites the LiverRisk score, a developing test he describes as "substantially superior" to other biomarkers. His group is currently working with NHANES data to see whether this is predictive for patients who had transient elastography and met MASH criteria. He particularly wants to determine whether this is a dynamic test. Michael goes on to discuss the work his group is doing on the microbiome, where he and others are finding potentially valuable insights. The challenge continues to be how to translate these insights into clinically meaningful interventions.

This is my interview on The Business of Doing Business podcast with Dwayne Kerrigan. n this episode, join host Dwayne Kerrigan and guest Dr. Greg Wells as they dive deep into the realms of entrepreneurship, personal growth, and the science behind achieving less stress and more success. Dr. Greg Wells is a master in exercise and respiratory physiology, an endurance sports enthusiast, and an adventurer at heart. He forecasts how AI could revolutionize education and automate 'hustle and focus' tasks, allowing for more strategic thinking and creativity. Dr. Greg Wells shares the untapped potential of breathing, movement, and mindset in unlocking true entrepreneurial success. At 15, a life-altering injury during a bodysurfing mishap didn't deter Dr. Greg Wells's determination to return to competitive swimming. Through months of recovery and unwavering support, he not only fully healed but excelled, racing at Olympic Trials and later pursuing degrees in kinesiology. Now a scientist and performance physiologist, Dr. Greg Wells explores human potential at the extremes, contributing to ground-breaking research. He serves as a scientist in Translational Medicine at the Hospital for Sick Children, which combines his passion for science advocacy and improving children's lives through physical activity. With over 60 published papers and $1 million raised for research, Dr. Greg Wells has shared stages with influential figures like Richard Branson and has authored five best-selling books, demystifying science. As CEO of Wells Performance, he has collaborated with global leaders and organizations, aiming to enhance lives both personally and professionally. Dr. Greg Wells's diverse experiences, from hosting the Gemini Award-Winning Superbodies series to continuing endurance sports and expeditions, fuel his mission to inspire others to stretch their boundaries and unlock their full potential. --- Support this podcast: https://podcasters.spotify.com/pod/show/dr-greg-wells/support

Isaac is investigating the role of CHIP mutations and inflammation in pulmonary arterial hypertension, while Sofia is examining the impact of BMPR-II loss on blood vessel growth in pulmonary arterial hypertension.  Two different angles, but it is still in relation to pulmonary arterial hypertension. For upcoming interviews check out the Grad Chat webpage on Queen’s University […]

A physician-scientist father shares his heartbreaking story of the death of his daughter who was diagnosed with Tay-Sachs disease and how it motivated him to become the CEO of JScreen to prevent this experience in other families.  Matt Goldstein is a physician-scientist and entrepreneur. He has founded companies, built R&D teams, and led strategy and execution of both pre-clinical research and clinical development. Prior to joining JScreen and Emory University, Matt was a Partner at Related Sciences, a venture creation firm. As an entrepreneur at Third Rock Ventures he spent a decade building and operating Third Rock portfolio companies. He was responsible for building and leading the Immunology program at Tango Therapeutics, the centerpiece of Tango's strategic multi-billion dollar partnership with Gilead Sciences, Inc. He also served as the development head for Tango's lead program which entered the clinic in 1H 2022. Matt was a co-founder of Neon Therapeutics leading Translational Medicine and Early Development through completion of their first clinical study and initial public offering. He is a graduate of Swarthmore College and the MD/PhD program at Stanford University, where he pioneered novel cancer immunotherapies in the lab of Ron Levy, MD. He completed his clinical training in Internal Medicine at Harvard Medical School, Brigham & Women's Hospital. He lives in Boston with his wife, Myra, their second daughter Kaia and son Ezra. His oldest daughter Havi died on January 20th, 2021 of Tay-Sachs disease. A quick update that during the episode Matthew mentioned there are 4,000 genetic counselors in the USA, this number has now surpassed 5,000.   During the episode, Matthew recommends the book Bearing the Unbearable: Love, Loss, and the Heartbreaking Path of Grief by Dr. Joanne Cacciatore.    Check out his wife, Myra's organization, Emotion, which is for grieving individuals to find community and cope with loss.    In our next episode we will chat with Myra about Emotion and her upcoming book, Fifty-Seven Fridays, which consists of memoirs from Matt and Myra, Havi's diagnosis, and how they celebrated her life.    Stay tuned for the next new episode of It Happened To Me! In the meantime, you can listen to our previous episodes on Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “It Happened To Me”.    “It Happened To Me” is created and hosted by Cathy Gildenhorn and Beth Glassman. DNA Today's Kira Dineen is our executive producer and marketing lead. Amanda Andreoli is our associate producer. Ashlyn Enokian is our graphic designer.   See what else we are up to on Twitter, Instagram, Facebook, YouTube and our website, ItHappenedToMePod.com. Questions/inquiries can be sent to ItHappenedToMePod@gmail.com. 

The importance of understanding the connections between animal and human health reached new heights due to the COVID-19 pandemic, but this has long been a rich area of study and it's also the foundation of the long and impressive career of today's Raise the Line guest, Dr. Sue VandeWoude, dean of the College of Veterinary Medicine and Biomedical Sciences at Colorado State University. Before assuming that role, Dr. VandeWoude was the director of Colorado State's One Cure Institute, part of an advanced veterinary oncology center whose work on a canine bone cancer is supporting a clinical trial in children with the same disease, among other translational projects. “That's a great example of where we seek to make progress in many different realms,” she tells host Hillary Acer. In this revealing conversation, you'll learn about other developments in research and teaching at the nexus of human, animal, and environmental health, what's behind a curricular overhaul at the school, and about plans to enhance collaboration between basic science faculty and clinical instructors. Mentioned in this episode: https://vetmedbiosci.colostate.edu/

In this episode of Nutrition Pearls: the Podcast, co-hosts Jen Smith and Melissa Talley speak with Brock Williams PhD, RD, CNSC about dietitians in research.  Dr. Brock Williams is a Registered Dietitian and a Post-Doctoral Research Fellow in the Division of Allergy at the University of British Columbia in Vancouver, Canada. Brock completed his PhD in Human Nutrition in 2023. Over the past 9 years, he has worked as both a research and clinical dietitian at the Hospital for Sick Children (SickKids) in Toronto, and at BC Children's Hospital in Vancouver in areas such as Translational Medicine, GI/Hepatology/Nutrition, and Allergy. His primary research and clinical interests lie in micronutrients, human milk feeding, and food allergy prevention and treatment. Nutrition Pearls is supported by an educational grant from Reckitt Mead Johnson Nutrition.Resources: Crafting academic abstracts/papers: https://writing.wisc.edu/handbook/assignments/. Gray et al. Innovative poster designs: A shift toward visual representation of data. Am J Health-Syst Pharm. 2022; 79(8):625-628Produced by: Melissa TalleyNASPGHAN - Council for Pediatric Nutrition Professionalscpnp@naspghan.org

In this episode, join host Dwayne Kerrigan and guest Dr. Greg Wells as they dive deep into the realms of entrepreneurship, personal growth, and the science behind achieving less stress and more success. Dr. Greg Wells is a master in exercise and respiratory physiology, an endurance sports enthusiast, and an adventurer at heart. He forecasts how AI could revolutionize education and automate 'hustle and focus' tasks, allowing for more strategic thinking and creativity. Dr. Greg Wells shares the untapped potential of breathing, movement, and mindset in unlocking true entrepreneurial success.At 15, a life-altering injury during a bodysurfing mishap didn't deter Dr. Greg Wells's determination to return to competitive swimming. Through months of recovery and unwavering support, he not only fully healed but excelled, racing at Olympic Trials and later pursuing degrees in kinesiology.Now a scientist and performance physiologist, Dr. Greg Wells explores human potential at the extremes, contributing to ground-breaking research. He serves as a scientist in Translational Medicine at the Hospital for Sick Children, which combines his passion for science advocacy and improving children's lives through physical activity.With over 60 published papers and $1 million raised for research, Dr. Greg Wells has shared stages with influential figures like Richard Branson and has authored five best-selling books, demystifying science. As CEO of Wells Performance, he has collaborated with global leaders and organizations, aiming to enhance lives both personally and professionally.Dr. Greg Wells's diverse experiences, from hosting the Gemini Award-Winning Superbodies series to continuing endurance sports and expeditions, fuel his mission to inspire others to stretch their boundaries and unlock their full potential.Connect with Dwayne KerriganLinked In: https://www.linkedin.com/in/dwayne-kerrigan-998113281/ Facebook: https://www.facebook.com/businessofdoingbusinessdk Instagram: https://www.instagram.com/thebusinessofdoingbusinessdk/Disclaimer The views, information, or opinions expressed by guests during The Business of Doing Business are solely those of the individuals involved and do not necessarily represent those of Dwayne Kerrigan and his affiliates. Dwayne Kerrigan or The Business of Doing Business is not responsible for and does not verify the accuracy of any of the information contained in the podcast series. The primary purpose of this podcast is to educate and inform. Listeners are advised to consult with a qualified professional or specialist before making any decisions based on the content of this podcast.

Professor Jasmin Tiro is a professor of Public Health Sciences at the University of Chicago She is the Associate Director of Cancer Prevention and Population Science at the NCI-Designated Comprehensive Cancer Center at the University of Chicago. Her program of research identifies multi-level determinants of cancer prevention and early detection behaviors. She uses quantitative and qualitative methods to develop, test, and implement interventions.  In 2014, Professor Tiro received the Outstanding Mentorship Award from the Center for Translational Medicine at UT Southwestern. In this episode, you will hear her share how her passion for science and experiments led her to the field of Public Health.

Dr. Malin, renowned for his work in utilizing exercise as a therapeutic intervention against obesity, type 2 diabetes, and cardiovascular disease, shares his insights on the optimal timing and type of exercise for managing these conditions. The discussion also touches on the physiological and behavioral aspects of circadian rhythms, offering a nuanced understanding of personalized healthcare approaches. --- In this insightful episode of the Physical Activity Researcher Podcast, host Dr. Olli Tikkanen engages in a comprehensive dialogue with Dr. Steven Malin, the esteemed Director of the Applied Metabolism & Physiology Laboratory (AMP Lab). Dr. Malin, who holds significant roles in medicine and is affiliated with both the New Jersey Institute for Food, Nutrition and Health and the Institute for Translational Medicine and Science, delves into the intricate relationship between exercise, circadian rhythms, and chronic diseases such as type 2 diabetes and cardiovascular conditions. The conversation explores the concept of circadian misalignment and its impact on health, particularly focusing on how individual chronotypes (morning or evening preferences) influence exercise effectiveness and overall well-being. Dr. Malin, renowned for his work in utilizing exercise as a therapeutic intervention against obesity, type 2 diabetes, and cardiovascular disease, shares his insights on the optimal timing and type of exercise for managing these conditions. The discussion also touches on the physiological and behavioral aspects of circadian rhythms, offering a nuanced understanding of personalized healthcare approaches. Listeners, primarily researchers in physical activity and related fields, will find this episode particularly enriching as it combines scientific depth with practical implications, underscoring the importance of tailoring exercise prescriptions to individual circadian preferences for enhanced health outcomes. ___________________ This podcast episode is sponsored by Fibion Inc. | Better Sleep, Sedentary Behaviour and Physical Activity Research with Less Hassle --- Learn more about Fibion Sleep and Circadian Rhythm Solutions: https://sleepmeasurements.fibion.com/ --- Collect, store and manage SB and PA data easily and remotely - Discover ground-breaking Fibion SENS: https://sens.fibion.com/ --- SB and PA measurements, analysis, and feedback made easy.  Learn more about Fibion Research : fibion.com/research --- Fibion Kids - Activity tracking designed for children. https://fibionkids.fibion.com/ --- Collect self-report physical activity data easily and cost-effectively https://mimove.fibion.com/ --- Follow the podcast on Twitter https://twitter.com/PA_Researcher Follow host Dr Olli Tikkanen on Twitter https://twitter.com/ollitikkanen Follow Fibion on Twitter https://twitter.com/fibion https://www.youtube.com/@PA_Researcher

Dr. Malin, known for his research on using exercise as a therapeutic tool against obesity, type 2 diabetes, and cardiovascular disease, shares insights into how individual chronotypes – whether one is an early bird or a night owl – can significantly influence exercise effectiveness and overall health. ----- In this enlightening episode of the Physical Activity Researcher Podcast, host Dr. Olli Tikkanen engages in a thought-provoking conversation with Dr. Steven Malin, Director of the Applied Metabolism & Physiology Laboratory (AMP Lab). Dr. Malin, a distinguished figure in medicine and an affiliate of the New Jersey Institute for Food, Nutrition and Health and the Institute for Translational Medicine and Science, delves into the complex relationship between exercise, chronotypes, and the management of type 2 diabetes. The discussion navigates through the nuances of exercise prescription, emphasizing the importance of personal preferences and the timing of physical activities. Dr. Malin, known for his research on using exercise as a therapeutic tool against obesity, type 2 diabetes, and cardiovascular disease, shares insights into how individual chronotypes – whether one is an early bird or a night owl – can significantly influence exercise effectiveness and overall health. The conversation also explores the impact of societal norms and circadian rhythms on physical activity patterns and disease risk, offering a fresh perspective on personalized healthcare. Listeners, predominantly researchers in the field, will find this episode particularly valuable as it blends scientific rigor with practical implications, highlighting the need for a more tailored approach to exercise and health management. ___________________ This podcast episode is sponsored by Fibion Inc. | Better Sleep, Sedentary Behaviour and Physical Activity Research with Less Hassle --- Learn more about Fibion Sleep and Circadian Rhythm Solutions: https://sleepmeasurements.fibion.com/ --- Collect, store and manage SB and PA data easily and remotely - Discover ground-breaking Fibion SENS: https://sens.fibion.com/ --- SB and PA measurements, analysis, and feedback made easy.  Learn more about Fibion Research : fibion.com/research --- Fibion Kids - Activity tracking designed for children. https://fibionkids.fibion.com/ --- Collect self-report physical activity data easily and cost-effectively https://mimove.fibion.com/ --- Follow the podcast on Twitter https://twitter.com/PA_Researcher Follow host Dr Olli Tikkanen on Twitter https://twitter.com/ollitikkanen Follow Fibion on Twitter https://twitter.com/fibion https://www.youtube.com/@PA_Researcher

CIRM-funded Alpha Stem Cell Clinics are a network of California medical centers that specialize in delivering stem cell clinical trials to patients. In this fascinating panel, clinic directors discuss advanced treatments, therapies like gene editing, and sharing knowledge and creating networks across the country for better patient care. Featuring: Geoffrey Lomax, Dr.PH California Institute for Regenerative Medicine Esther and Andrew Schorr Patient Advocates Sandra Dillon Cancer Survivor and Stem Cell Champion Catriona Jamieson, M.D., Ph.D. UC San Diego Mehrdad Abedi, M.D. UC Davis Daniela A. Bota, M.D., Ph.D. UC Irvine Sheila Chari, Ph.D. Cell Press Leo D. Wang, M.D., Ph.D. City of Hope National Medical Center Mark Walters, M.D. University of California, San Francisco Thomas Buchanan, M.D. University of Southern California Michael Lewis, M.D. Cedars Sinai Noah Federman, M.D. UCLA Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 39070]

CIRM-funded Alpha Stem Cell Clinics are a network of California medical centers that specialize in delivering stem cell clinical trials to patients. In this fascinating panel, clinic directors discuss advanced treatments, therapies like gene editing, and sharing knowledge and creating networks across the country for better patient care. Featuring: Geoffrey Lomax, Dr.PH California Institute for Regenerative Medicine Esther and Andrew Schorr Patient Advocates Sandra Dillon Cancer Survivor and Stem Cell Champion Catriona Jamieson, M.D., Ph.D. UC San Diego Mehrdad Abedi, M.D. UC Davis Daniela A. Bota, M.D., Ph.D. UC Irvine Sheila Chari, Ph.D. Cell Press Leo D. Wang, M.D., Ph.D. City of Hope National Medical Center Mark Walters, M.D. University of California, San Francisco Thomas Buchanan, M.D. University of Southern California Michael Lewis, M.D. Cedars Sinai Noah Federman, M.D. UCLA Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 39070]

CIRM-funded Alpha Stem Cell Clinics are a network of California medical centers that specialize in delivering stem cell clinical trials to patients. In this fascinating panel, clinic directors discuss advanced treatments, therapies like gene editing, and sharing knowledge and creating networks across the country for better patient care. Featuring: Geoffrey Lomax, Dr.PH California Institute for Regenerative Medicine Esther and Andrew Schorr Patient Advocates Sandra Dillon Cancer Survivor and Stem Cell Champion Catriona Jamieson, M.D., Ph.D. UC San Diego Mehrdad Abedi, M.D. UC Davis Daniela A. Bota, M.D., Ph.D. UC Irvine Sheila Chari, Ph.D. Cell Press Leo D. Wang, M.D., Ph.D. City of Hope National Medical Center Mark Walters, M.D. University of California, San Francisco Thomas Buchanan, M.D. University of Southern California Michael Lewis, M.D. Cedars Sinai Noah Federman, M.D. UCLA Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 39070]

Embark on a transformative health journey with Dr. Sarah Zielsdorf, a board-certified internist and microbiologist who harnessed microbiology to combat her chronic illness. Dr. Zielsdorf unravels the complexities of our biological clocks, the nuances of gut health, and the power of functional foods in nurturing a balanced microbiome.Dr. Zielsdorf shares profound insights into the synchronization of our natural circadian rhythms, the efficacy of specific prebiotics and probiotics, and the role of functional foods in maintaining a robust microbiome. We cover diverse topics, including effective doctor-patient communication strategies, overcoming healthcare system challenges, and the importance of targeted hormonal and microbiome assessments. Dr. Zielsdorf sheds light on the significance of compounded hormones and thyroid treatments in contemporary healthcare.We also explore the fascinating history and benefits of the E. coli strain Nissle 1917, utilized as a probiotic in Europe. Concluding our dialogue, Dr. Zielsdorf imparts practical strategies and personal insights, emphasizing the power of informed choices in promoting longevity and optimal health.Tune into this episode to revolutionize your perspective on health, wellness, and professional practice. Subscribe for more thought-provoking episodes!Chapters:(00:00) - Microbes and Health Influence in Chronobiology(06:08) - Translational Medicine and the Gut Microbiome(16:32) - Prebiotics, Probiotics, and Referring Specialists(26:48) - Challenges and Benefits of Doctor-Patient Communication(32:44) - The Use and Benefits of Probiotics(44:03) - Compounding Pharmacists and Advocacy for Access(49:29) - Expressing Gratitude and Promoting Podcast ContentLinks:Motivated MedicineJoin Over 18,000 Leading Medical Professionals and Become a Vibrant Wellness Provider Today!

Synopsis: Brett Hall, Ph.D., is the CSO of Immuneering, a public, clinical-stage oncology company dedicated to developing medicines for broad populations of cancer patients by applying its deep knowledge of translational bioinformatics to every stage of the drug development process. Brett talks about his background in the military targeting nuclear missiles prior to becoming a scientist and some of the commonalities between working in the military and pharma/biotech. He shares his thoughts on AI and machine learning in drug development. He talks about Immuneering's disease-agnostic platform that enables the company to utilize human data, novel biology and chemistry, and translational planning to create and advance its pipeline. Finally, he discusses their focus on oncology and providing potential treatments for patients with advanced solid tumors. Biography: Brett Hall, Ph.D. has served as Chief Scientific Officer of Immuneering since November 2019. He also served as the Founder and Chairman of the board of directors of BioArkive, Inc., or BioArkive, a privately held biotechnology services company from January 2019 until December 2021. Prior to joining Imuneering, Dr. Hall served as the Chief Executive Officer of Asellus Therapeutics, LLC from July 2015 until May 2018. Dr. Hall served in roles of increasing responsibility with Johnson & Johnson from November 2008 until July 2014, culminating in his role as the Head of Biomarkers of the Hematologic Disease Area Stronghold, where he led translational efforts for Sylvant® and Imbruvica® through clinical development. Subsequently, he served as the Head of Translational Medicine of Oncology at Medimmune, LLC, the biologics division of AstraZeneca Pharmaceuticals LP, from July 2014 until July 2015, before transitioning to executive discovery roles in biotechnology. He has extensive drug development and leadership experience ranging from early drug discovery through translational clinical sciences, including multiple drug registrations. Dr. Hall has extensively published in the areas of tumor microenvironment (TME) and translational sciences, and holds multiple patents for drug pharmacology and discovery. He was also a tenure-track Assistant Professor at Ohio State University where his laboratory focused on the development of human TME-aligned models to better translate preclinical data into the clinic and discover novel biomarkers. Prior to Dr. Hall's career in life sciences, he served in the United States Air Force and worked as an investment banker. Dr. Hall received his B.S. in biochemistry from Ohio State University, his Ph.D. in immunology and cancer biology from West Virginia University, and completed his post-doctoral fellowship in cancer cell epigenetics at St. Jude Children's Research Hospital.

A perpetual student of higher education and advanced learning, Dr Wendy Gulden comes with 20 years of experience practicing endodontics in Minnesota and California. She graduated from the University of Minnesota with her DDS and MS degree where she practiced in a group practice and opened her own office. She followed her desire to move to a warmer climate and moved to San Francisco where she practiced for 7 years. The desire for higher learning returned and she attended the University of California, Berkeley where she earned a Masters in Translational Medicine which allowed her to serve in bridging the gap between technology and unmet needs. Her training, education and cross functional strategies have been instrumental as the current Medical Affairs Manager at Sonendo. Dr. Gulden enjoys her free time living in Laguna Beach, biking, playing tennis, practicing yoga and enjoying sunset beach evenings. She is married with two college bound children.

Al Stahler talks with University of Montana professor, Jay Evans. Evans directs the UM Center for Translational Medicine, which is working on a vaccine to prevent fentanyl and heroin drug overdoses.

Syd Brown takes us for A Walk In The Park and Al Stahler talks with University of Montana professor, Jay Evans. Evans directs the UM Center for Translational Medicine, which is working on a vaccine to prevent fentanyl and heroin drug overdoses.The California Report heads to the central coast to explain how the “Clean Airport Agenda” will compel federal agencies to phase out the use of polyfluoroalkyl substances (PFAS).

This episode's Community Champion Sponsor is Catalyst. To virtually tour Catalyst and claim your space on campus, or host an upcoming event: CLICK HERE---Episode Overview: During this episode, we chat with Narinder Singh, co-founder, and CEO of LookDeep Health, an innovative company leveraging AI and computer vision to revolutionize virtual care in the hospital. Motivated by his mother's harrowing healthcare journey, Narinder brings an outsider's perspective to solving systemic access issues of continuously monitoring patients that drive healthy outcomes. While together, Narinder shares how LookDeep Health enables hospital-wide video surveillance through affordable hardware and software, while nudging providers' attention via AI. Narinder unpacks the virtual command center experience for clinicians and feedback from nurses who feel they finally "have more resources" with LookDeep's technology. We also discuss the measured approach to implementing human and AI collaboration and the mindset shifts required in skeptical healthcare settings. Join us to gain inspiration from Narinder's passion for applying technology to ease care provider burdens and keep patients safe. Let's go! Episode Highlights:Narinder's personal healthcare crisis revealed gaps in hospital care and monitoring.LookDeep uses computer vision and AI to monitor patients hospital-wide continuously.Affordable hardware model enables ubiquitous video surveillance and virtual monitoring.Feedback shows nurses feel like they "have more resources" supporting patients.Thoughtful change management is key for human-AI collaboration in healthcare. About our Guest: Narinder is co-founder and CEO of LookDeep Health. Prior to that, he was co-founder and president of Appirio, a pioneer in cloud computing and the first cloud investment of Salesforce.com and Sequoia Capital. Appirio grew to over 1,200 employees and was acquired by Wipro in 2016. Previous to Appirio, Narinder worked in the Office of the CEO at SAP and ran product development at webMethods.He holds a BS from Northwestern, an MBA from The Wharton School of the University of Pennsylvania and Masters in Translational Medicine from The University of California, San Francisco and Berkeley. He serves on the boards of Par Technologies (NYSE:PAR) and the Sikh Coalition.Links Supporting This Episode:LookDeep Health Website: CLICK HERENarinder Singh LinkedIn page: CLICK HERENarinder Singh Twitter page: CLICK HERE Mike Biselli LinkedIn page: CLICK HEREMike Biselli Twitter page: CLICK HEREVisit our website: CLICK HERESubscribe to newsletter: CLICK HEREGuest nomination form: CLICK HERE

Hear the extraordinary journey of a leading Trauma Consultant and how he struggled during his early life against all odds. Mr Ansar Mahmood shares life lessons that are applicable to all of us. Key topics covered in this episode:

Why You Should Listen:  In this episode, you will learn about unraveling Bartonella. About My Guest: My guest for this episode is Dr. B. Robert Mozayeni.  B. Robert Mozayeni, MD is an expert in Translational Medicine, the science and art of advancing medical science safely and efficiently.  He is the Chief Medical Officer of Galaxy Diagnostics, LLC.  He is a co-founder of the Foundation for the Study of Inflammatory Diseases.  He serves as an advisor to pharmaceutical and nutraceutical companies and serves on an Institutional Review Board specializing in nutraceutical products for pain management.  He is the immediate past President of ILADS, the International Lyme and Associated Diseases Society where his goal was to advance the science of translational medicine.  In late 2019, Dr. Mozayeni launched T Lab Inc., a research and clinical laboratory engaged in research using advanced microscopy to understand better the pathogenesis of disease in inflammatory conditions associated with persistent infections.  He has research and clinical expertise with regard to autoimmune diseases and the effects of chronic infection and inflammation on vascular physiology and neurovascular conditions seen commonly with autoimmune and neurovascular diseases.  With a strong foundation in the basic sciences and evidence-based medicine, he analyzes complex medical cases using a combination of basic scientific principles and clinical experience along with the balance of the evidence base.  Dr. Mozayeni has published numerous papers on immunology and cerebrovascular blood flow hemodynamics.  He has been actively researching and publishing his work on chronic rheumatic diseases and their relationship to persistent human Bartonella spp. infection.  Of note, chronic persistent Bartonella spp. infections are strongly associated with neurovascular diseases.  Thus, Dr. Mozayeni is uniquely qualified in the combined areas of chronic persistent endovascular infections and related rheumatological and neurovascular diseases.  He has also published papers providing new insights as to a potential infectious  (Bartonella spp.) cause of osteoarthritis and also, a case of arthritis associated with hypermobility that was likely caused by Bartonella spp. Key Takeaways: What advances have been observed in recent years in the realm of Bartonella? What are common symptoms of Bartonella? How is Bartonella transmitted? Might Bartonella lead to autoimmunity? Can Bartonella be a trigger for PANS? Might Bartonella be a contributor to osteoarthritis? Is there a connection between Bartonella and hypermobility or EDS? Does Bartonella contribute to MS? What is the connection between Bartonella and SIBO? Can Bartonella act as a trigger for MCAS? Is Bartonella activation observed in those with COVID? What is the state of the art in Bartonella testing? What is Babesia odocoilei? What agents are most helpful in the treatment of Bartonella? Is there a place for herbs and other natural interventions in Bartonella treatment? Should pets be considered as a potential source of exposure to Bartonella? Connect With My Guest: http://TMGMD.com Related Resources: Article: Unraveling the Mystery of Bartonellosis Interview Date: May 24, 2023 Transcript: To review a transcript of this show, visit https://BetterHealthGuy.com/Episode185. Additional Information: To learn more, visit https://BetterHealthGuy.com. Disclaimer:  The content of this show is for informational purposes only and is not intended to diagnose, treat, or cure any illness or medical condition. Nothing in today's discussion is meant to serve as medical advice or as information to facilitate self-treatment. As always, please discuss any potential health-related decisions with your own personal medical authority. 

Dr. Steve James is now an assistant professor in the Department of Translational Medicine and Physiology at Washington State University, having previously served for over 20 years in the British military. He has since become one of the US's foremost experts on the effects of fatigue and sleep deprivation on law enforcement. He outlines a range of practical ways police officers can manage their sleep, coffee and stimulant intake, overtime, and seasonal changes.

Join 250 Medtech entrepreneurs, start-ups, and entrepreneurial organizations from across North America. Register now for a full day of medical device commercialization information and inspiration. STANTON J. ROWE Founder & CEO, NXT Biomedical Incubator - Former Chief Scientific Officer and Corporate Vice President of Advanced Technology of Edwards Lifesciences Corp. PAUL LOVOI, PH.D. Co-Founder and CTO, MindRhythm Inc. - Serial entrepreneur of eight companies DEEPIKA A. LAKHANI PH.D. Vice President of Regulatory & Quality, PAVmed Inc. - Former FDA Team Leader and Corporate Regulatory Affairs Expert GREGG HOMER, JSD (PH.D.) - CHAIRMAN AND CHIEF SCIENCE OFFICER AT STRŌMA MEDICAL CORPORATION Invented instant coffee bags at age 12, patented “subscription on demand”, leader in permanent eye color change From Entertainment Law to Eye Color Change: What a Long Strange Trip It's Been EARL SLEE, BOARD MEMBER OR ADVISOR TO SIX MEDTECH ORGANIZATIONS (Retired) Vice President, Technology, Strategy and Business Development, Medtronic Brain Therapies How strategic acquirers determine value Case Studies in Strategic Exits RAMGOPAL RAO Chief Executive Officer, LensGen, Inc. - serial entrepreneur with 25 years of experience in the ophthalmic pharmaceutical and devices Going after the Holy Grail of Ophthalmology - The LensGen story How it happened and lessons learned. BILL WALKER PH.D. Director of Entrepreneurship, Duke Engineering - Inventor, serial entrepreneur, and educator Finding the Sweet Spot: How to Balance the Right Idea, Execution, and Culture in a Medtech Startup: Perspectives as a Player and a Coach YIORGOS POLIZOS VP of Sales and Marketing, Life Science Outsourcing (LSO) YOAV RAITER, CHIEF EXECUTIVE OFFICER AND DIRECTOR OF SCRYB AND CYBEATS Developer of innovative software and medical device products Why SBOMs are Critical to Managing Medical Device Software Supply Chain RYAN KELLY, PH.D., MBA General Manager, Innovation Lab Getting Value from strategic Health System Partners Industry Panel PABLO AVALOS Associate Director of Translational Medicine, Regenerative Medicine Institute Getting Value from strategic Health System Partners Industry Panel RYAN DOUGLAS Co-Founder, Deepwell, NeuFluent / Founder, Nextern Power Play – Where therapeutic benefit meets market realities MATT MITCHO Co-Founder & CEO, Gemelli Biotech Getting Value from strategic Health System Partners Industry Panel MICHAEL HILL Managing Director of Octane Capital Markets, Octane Capital & Growth NICK ALLAN, BIO SERVICES MANAGER AT STARFISH MEDICAL Designed, Facilitated, and Executed more than 500 Unique Research Protocols and Medical Device 510(k) Antimicrobial Support packages Developing the World's First Ingestible Digital Fluorometric Laboratory: From First Principles to First In Human SCOTT PHILLIPS CEO and Founder, StarFish Medical

DO NOT MISS THIS EPISODE! Need a little inspiration? Tune in for Dave's story. Links from the show:  Chasing My Cure: https://chasingmycure.com/ CDCN: https://cdcn.org/ Every Cure: https://everycure.org/ AMF: https://healgrief.org/actively-moving-forward/young-adult-grief/ David Fajgenbaum, MD, MBA, MSc, FCPP, is an Assistant Professor of Medicine in Translational Medicine & Human Genetics at the University of Pennsylvania, Founding Director of the Center for Cytokine Storm Treatment & Laboratory (CSTL), Associate Director, Patient Impact of the Penn Orphan Disease Center, and Co-Founder/President of the Castleman Disease Collaborative Network (CDCN) and co-founder of Every Cure. He is also the national bestselling author of 'Chasing My Cure: A Doctor's Race to Turn Hope Into Action' and a patient battling idiopathic multicentric Castleman disease (iMCD). He is in his longest remission ever thanks to a precision treatment that he identified, which had never been used before for iMCD. He has also identified and/or advanced 9 other treatment approaches for iMCD and cancer.  One of the youngest individuals ever appointed to the faculty at Penn Medicine and in the top 1 percent youngest awardees of an NIH R01 grant, Fajgenbaum has published scientific papers in high-impact journals such as the New England Journal of Medicine, Journal of Clinical Investigation, and Lancet, been recognized with awards such as the 2016 Atlas Award along with then Vice President Joe Biden, and profiled in a cover story by The New York Times as well as by Good Morning America, CNN, Forbes 30 Under 30, and the Today Show. An authority on cytokine storms and their treatment, Fajgenbaum currently leads over 20 translational research studies including the CORONA Project, which is the world's largest effort to identify, track, and advance COVID-19 treatments. He also serves on the Board of Directors for the Reagan-Udall Foundation for the FDA, co-Chair of the Advisory Board for the CURE Drug Repurposing Collaboratory, and co-Chair of the Scientific Advisory Board for the CDCN.  Dr. Fajgenbaum earned a BS in Human Sciences with Distinction from Georgetown University, where he was USA Today Academic All-USA First Team and a Quarterback on the Division I football team, a MSc in Public Health from the University of Oxford as the 2007 Joseph L. Allbritton Scholar, a MD from the Perelman School of Medicine at the University of Pennsylvania, where he was a 21st Century Gamble Scholar, and a MBA from The Wharton School, where he was awarded the Joseph Wharton Award, Core Value Leadership Award, Kissick Scholarship, Wharton Business Plan Competition Social Impact Prize, Eilers Health Care Management Award, Mandel Fellowship, and Commencement Speaker. Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our other recent episodes here: https://behindtheknife.org/listen/

Chas Bountra, PhD, Pro Vice-Chancellor for Innovation & Professor for Translational Medicine at the University of Oxford, and Jim Weiss, Founder & CEO of Real Chemistry, join this week's episode to discuss accelerating healthcare through novel ideas and the importance of collaborating across organizations, industries and countries. 

Video: Nothing is more anti-woman than this. Gen Z Refuses to Grow Up | With Dr. Jean Twenge   Tomato extract shows blood thinning potential versus aspirin: Study University of Aberdeen (Scotland), November 23, 2022 A proprietary tomato extract has been shown to thin blood in healthy people – but less severely than aspirin and without typical side-effects. The research – published in the European Journal of Clinical Nutrition concluded the lycopene-free extract “may be appropriate for use as a dietary antiplatelet.” Lead researcher Dr Niamh O'Kennedy working at the Rowett Institute of Nutrition & Health at the University of Aberdeen in Scotland told us the research showed tomato extracts could be used as alternatives to drugs like aspirin for blood thinning. This was especially the case for groups like the elderly who frequently were intolerant of drugs like aspirin typically prescribed for that purpose. “Platelet function is very tricky,” Dr O'Kennedy told us. “If you knock out the platelets it can have a bad effect on the body. And many treatments knock out too much. Some people respond strongly so bad they bleed. ” She added: “Results like this show that people and the medical world should start looking at dietary interventions like these that can have a big impact.” Platelet plugs usually form within 50-100 seconds. The researchers found platelet plugs were formed within 100-150 seconds among tomato extract users, compared to 300-600 seconds for aspirin users. Because of this more gentle effect, Dr Kennedy and her team suggested tomato extract could be a suitable dietary intervention to control platelet hyperactivity which increases with age, the onset of type II diabetes, mellitus, atherosclerosis and other conditions in subjects with low cardiovascular disease (CVD) risk. (Next) Use of penicillin early in life, even in low doses, affects the gut microbiome, contributing to brain inflammation and changes in behavior McMaster University (Ontario), November 18, 2022 It is truly unavoidable to catch a cold or contract a disease, especially with today's lifestyle trends and medical misinformation. A lot of the medicine we use to treat our health conditions may actually cause more harm than good. A St. Joseph's Healthcare Hamilton and McMaster University joint study found that low doses of penicillin administered to pregnant mice and their young results in behavioral changes that have long-term effects. The study, which was published in Nature Communications, reports that the behavioral changes noted in the mice included elevated levels of aggression, characteristic neurochemical changes in the brain, and imbalance in the gut microbiome of the mice. On the bright side, giving the mice a lactobacillus strain of bacteria managed to prevent the effects of the administered penicillin. Low-dose penicillin taken in late pregnancy and early life of mice offspring results in behavioral changes and imbalances in the microbes of the gut. While the tests were done on mice, there are increasing concerns about the long-term effects of antiobiotics in humans, according to Dr. John Bienenstock, director of the Brain-Body Institute at St. Joseph's Healthcare Hamilton and distinguished professor at McMaster University. Large doses of multipurpose antibiotics in adult animals have been shown to affect behavior, but none have been able to test the effects of clinical doses of commonly used antibiotics, such as penicillin, on the bacteria in the gut and in behavior. Almost all babies in North America have received some dose of antibiotics during their first year of life. Researchers are looking into analyzing the effects of the drug on the offspring of the mice if given only to the pregnant mothers (teratogenesis). Penicillin is the first type of medication that is effective against bacterial infections caused by staphylococci and streptococci, but is however, easy to build resistance against. Almost 10 percent of all people around the world are allergic to penicillin. (Next) High-dose vitamin C reduces inflammation in cancer patients, study shows Riordan Clinic (Wichita KS), November 22, 2022 The value and impact of a daily vitamin C supplement as well as high, concentrated doses for acute illnesses is becoming increasingly clear. Studies have already shown the efficacy of liposomal vitamin C in treating infections and as an anti-cancer therapy. Now, another study is confirming its effectiveness against inflammation in cancer patients, one of the primary markers. High levels of inflammation seem to indicate a higher risk of cancer as well as a less hopeful prognosis for healing and recovery. Inflammation impairs the immune system, plays a role in cachexia, lowers toleration of numerous cancer treatments, and generally decreases health and quality of life. This study made use of high-dose intravenous vitamin C (IVC) treatments and analyzed their effects. The results found indicate great promise for the use of high-dose intravenous vitamin C treatments to help reduce inflammation in cancer patients, which is one of the major factors of cancer and its progression. Markers of inflammation such as pro-inflammatory cytokines and C-reactive protein tumor markers showed a positive response to vitamin C treatments, with inflammation reduced significantly. This improvement correlated with reduced tumor size and the hindrance of the cancer's ability to metastasize. Vitamin C is especially valuable in extremely high doses taken either orally or intravenously. A range of cancers have been proven to benefit from vitamin C treatments, including cancers of the prostate, breast, skin, bladder, lung, pancreas, thyroid, and B-cell lymphoma. This research was conducted by Riordan Clinic scientists and published in the Journal of Translational Medicine. When supplementing with liposomal vitamin C orally for major health issues, 10,000 to 12,000 mg per day should be taken. This dose can be taken in 2,000 to 4,000 mg doses gradually throughout the day to aid absorption. (Next) Having trouble sleeping? Try exercise! Norwegian University of Science and Technology, December 1, 2022 The vast majority of people have trouble sleeping from time to time. However, 10 to 20 per cent of the population struggle more than the rest of us and have serious long-term sleep problems. Many people who struggle with insomnia sooner or later resort to some form of sleeping aid. However, one study of more than 34 000 adults would suggest that some of them should exercise instead. “We've observed that people who are in better physical condition have a lower risk of taking prescription sleeping pills,” says Linda Ernstsen, an associate professor at the Norwegian University of Science and Technology's (NTNU) Department of Public Health and Nursing. The researchers reviewed participant data in Norway's large Trøndelag Health Survey (The HUNT study). A total of 240 000 people from Trondheim have taken part in the survey since it began in 1984. Four survey rounds have been carried out to date. “Almost 5800 of the participants received their first prescription sleep medication during the study period,” says Ernstsen. This means that approximately 17 percent of the participants' sleep issues were serious enough to warrant a prescription from their doctor. But the participants who were in the best condition used fewer of these prescription drugs. “These findings suggest that being physically fit can also help you sleep better,” Ernstsen says. Unfortunately, the beneficial effect of exercise is stronger for men than for women. The findings show that the fittest men had a 15 per cent lower risk of needing drugs for troublesome sleep issues. “The corresponding percentage risk for the fittest women was much lower. But women who struggle with sleep can still benefit from getting in better shape,” says Ernstsen. (Next) New study puts gut microbiome at the center of Parkinson's disease pathogenesis University of Alabama at Birmingham, December 1, 2022 New research from the University of Alabama at Birmingham says the gut microbiome is involved in multiple pathways in the pathogenesis of Parkinson's disease (PD). The findings, published in Nature Communications, show a wide imbalance in microbiome composition in persons with Parkinson's disease. The study is the largest microbiome study conducted at the highest resolution. The investigators employed metagenomics, the study of genetic material recovered directly from the stool microbiome of persons with PD and neurologically healthy control subjects. “The primary aim of this study was to generate a full, unaltered view of the imbalance in PD gut microbiome,” said Haydeh Payami, Ph.D., professor in the Marnix E. Heersink School of Medicine Department of Neurology and senior author on the study. The study reports Parkinson's disease metagenome is indicative of a disease-promoting microbiome. “We found evidence for multiple mechanisms that we know are linked to PD, but we didn't know they were happening in the gut also and are orchestrated by the microbiome,” Payami said. Investigators found an overabundance of opportunistic pathogens and immunogenic components, which suggest infection and inflammation at play, overproduction of toxic molecules, and overabundance of the bacterial product curli. This induces PD pathology and dysregulation of neurotransmitters, including L-dopa. At the same time, there was a shortage of neuroprotective molecules and anti-inflammatory components, which makes recovery difficult. The researchers studied 257 species of organisms in the microbiome, and of these, analysis indicated 84, more than 30%, were associated with Parkinson's disease. “Of the 84 PD-associated species, 55 had abnormally high abundance in persons with PD, and 29 were depleted,” Payami said. “We found that over 30% of the micro-organisms and bacterial genes and pathways tested have altered abundances in Parkinson's disease, which indicates a widespread imbalance.” At one end of the spectrum, Bifidobacterium dentium was elevated by sevenfold, Actinomyces oris by 6.5-fold and Streptococcus mutans by sixfold. At the other end of the spectrum, Roseburia intestinalis was reduced by 7.5-fold and Blautia wexlerae by fivefold. Overall, 36% of PD-associated species had higher than twofold change in abundance, reflecting a 100% to 750% increase or decrease in PD versus the healthy control group. “This is exciting research, as metagenomics is a new, albeit fast-evolving field, and the resources, methods and tools, while state-of-the-art, are still in development,” Payami said. (Next) Five precepts of Buddhism may be linked to lower depression risk Study suggests the moral practice may buffer known links between high stress levels and depression Chiang Mai University (Thailand) & Károli Gáspár University (Hungary), November 30, 2022 A new study suggests that people with high levels of neuroticism and stress may be at greater risk for depressive symptoms, but those links could be buffered for people who observe the five precepts of Buddhism—a fundamental system of ethics for the religion's followers. The five precepts of Buddhism guide followers not to kill, steal, engage in sexual misconduct, tell ill-intentioned lies, or use intoxicants. Previous research suggests that observing the five precepts can boost wellbeing and quality of life for the general public, including nonserious followers. However, it has been less clear whether the five precepts could ease symptoms of depression for those at higher risk. To address this question, Wongpakaran and colleagues focused on known links between neuroticism, stress, and depression. Prior research has shown that greater neuroticism is associated with greater risk of depression, both directly as well as indirectly through perceived stress—how people think and feel after stressful life events. From late 2019 through September 2022, the researchers conducted an online survey of 644 adults in Thailand. The survey included standard questionnaires to measure each participant's levels of perceived stress, neuroticism, and depressive symptoms, as well as their observance of the five precepts of Buddhism. Statistical analysis of the survey results showed that observing the five precepts to a high degree appeared to buffer the influence of perceived stress on depression. These results suggests that people with high levels of neuroticism and stress may be less likely to develop depressive symptoms if they follow the five precepts closely. The researchers note that, while their study suggests potential benefits for the five precepts in the context of depression, it does not confirm a cause-effect relationship. A large proportion of participants were female and people who lived alone, and participants' religious involvement was unknown, although 93.3% reported that they were Buddhist. More research will be needed to determine whether these findings might extend to the general population of Thailand and beyond, as well as to non-Buddhists. The authors add: “The five precepts practice makes other people feel safe, as all these behaviors are harmless, and it potentially provides the stressful practitioner with a buffer against depression.”

Mike earned his B.S. in Biology from Western Washington University in 2006 and completed his M.S. in Clinical Nutrition from the University of Bridgeport in 2015 and is a graduate of the Institute for Functional Medicine's (IFM) Applying Functional Medicine in Clinical Practice (AFMCP). He is a Functional Medicine consultant in the natural product industry and has worked as a nutritionist with Gerard Guillory, MD of the Care Group, PC in Denver, CO. Mike has lectured alongside Dr. Guillory to large patient-groups in the Denver area and they have been featured on local T.V. programs discussing the power of Nutrition and Functional Medicine. In April of 2014 Mike published his first book, Belly Fat Effect: The Real Secret About How Your Diet, Intestinal Health, and Gut Bacteria Help You Burn Fat. To continue his quest for knowledge Mike attends many Continuing Medical Education (CME) events held by various organizations around the country, learning from top researchers in the field through groups like AACR, ACAM, A4M and IFM. He has currently completed four of six Advanced Practice Modules (APMs) to earn the only board certification in Functional Medicine through IFM. Mike regularly conducts workshops for health care practitioners, teaching leading-edge science in a concise format that can be utilized by progressive clinicians for the prevention of chronic disease. Often termed Translational Medicine, this bench-to-bedside approach is key to ensure the application of pioneering research and concepts in systems biology a preventative health care setting, optimizing patient outcomes. Mike lives in Kirkland, WA with his wife Deanna Arnill- a Doctor of Chiropractic- with their daughter and two dogs Shasta and Rainier. They enjoy cooking locally grown whole foods and adhere to an active outdoor life of skiing, hiking and biking. Dr. Deanna practices in the Seattle area and works with clients all over the world.